BPC-157 + TB-500: dosing evidence
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
Both peptides are typically given subcutaneously (SubQ); BPC-157 is often placed nearer the area of interest, while TB-500 acts systemically from any site. The figures below are a generalized reference drawn from research and clinic protocols, not a single standard.
This is a concise reference to regimens described for adults; it is not an individual prescription.
TB-500 (a synthetic Thymosin Beta-4 fragment) gets searched on its own more often than the BPC-157 combination, so this section covers TB-500 dosing within this blend specifically, not a general overview of the peptide.
| Period / condition | Dose | Escalation |
|---|---|---|
| Loading phase (weeks 1-4) | BPC-157 250-500 mcg/day SubQ + TB-500 2-2.5 mg twice weekly | Starting dose |
| Maintenance phase (weeks 5-8) | BPC-157 250 mcg/day + TB-500 2 mg weekly | Maximum in this schedule |
| Course length | 4-8 weeks (up to 12 for chronic cases) | , |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosage and effect notes
No controlled clinical data exist on dosing this specific combination, and the schedule on this page is drawn from public research protocols. Splitting it into a loading phase (weeks 1–4) and a maintenance phase (weeks 5–8) is common logic in those protocols: a higher starting dose is stepped down once a cumulative effect, as reported by users of the protocol, is established.
The two peptides' different frequency in the table (BPC-157 daily, TB-500 once or twice weekly) reflects the difference in administration model this page describes: BPC-157 is more often placed nearer the area of interest and injected more frequently, while TB-500 acts systemically from any site, so published protocols less often call for daily dosing to sustain a systemic effect.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.